Re-irradiation in progressive diffuse infiltrative pontine glioma in children and young adults
Open Access
- 25 March 2025
- journal article
- research article
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (9) , 894-902
Abstract
Purpose: This study aims to assess oncological outcomes in children and young adults with diffuse infiltrative pontine glioma (DIPG) who have progressed after initial radiotherapy (RT), with an emphasis on the role of re-irradiation. Methods: Data from 33 patients aged 25 years or younger with progressive disease after initial RT were retrospectively analyzed. Results: The median age at diagnosis was 8 years (range 4–24 years), and the median initial RT dose was 54 Gy (range 39–54 Gy). The median time between initial RT and progression was 8 months (range 3–40 months). In addition to systemic therapy, 15 patients (46%) received re-irradiation due to progression, with a median dose of 23.4 Gy (range 19.8–36 Gy), while 18 patients (54%) were treated with systemic therapy alone. In patients who received re-irradiation after progression, the 1‑year post-progression overall survival (OS) was significantly higher compared to those treated with systemic therapy alone (27% vs. 0%, p = 0.01). Among the 15 re-irradiated patients, 9 out of 12 with available data (75%) showed improvement in neurological symptoms following re-irradiation. No patient exhibited acute or late RT-related ≥ grade 3 toxicity. Conclusion: Palliative re-irradiation in children and young adults with progressive DIPG after initial RT provides an approximately 3‑month OS benefit and clinical improvement without significant toxicity and should be considered as a standard-of-care approach.Keywords
Funding Information
- Hacettepe University
This publication has 29 references indexed in Scilit:
- Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhoodJournal of Neuro-Oncology, 2014
- Preliminary experience with diffusion tensor imaging before and after re-irradiation treatments in children with progressive diffuse pontine gliomaChild's Nervous System, 2014
- Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy – Results of a United Kingdom phase II trial (CNS 2007 04)European Journal of Cancer, 2013
- Palliative Reirradiation for Progressive Diffuse Intrinsic Pontine GliomaAmerican Journal of Clinical Oncology, 2012
- Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experienceJournal of Neuro-Oncology, 2011
- Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine gliomaJournal of Neuro-Oncology, 2011
- Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology GroupNeuro-Oncology, 2011
- Prospective Evaluation of Radiotherapy With Concurrent and Adjuvant Temozolomide in Children With Newly Diagnosed Diffuse Intrinsic Pontine GliomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaNew England Journal of Medicine, 2005